Post-approval studies (Phase 4)Study completedNCT03853551What this trial is testingOsimertinib Study in Indian PatientsWho this might be right forNon Small Cell Lung Cancer (NSCLC) AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT03861156What this trial is testingD-0316 in Patients With EGFR Positive Non Small Cell Lung CancerWho this might be right forSolid TumorNSCLCEGFR T790M InventisBio Co., Ltd 290
Not applicableNo Longer AvailableNCT02451852What this trial is testingAZD9291 US Expanded Access ProgramWho this might be right forEGFR T790M Mutation Positive NSCLC AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT03513666What this trial is testingToripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI TreatmentWho this might be right forNSCLC Shanghai Junshi Bioscience Co., Ltd. 40
Not applicableStudy completedNCT03137264What this trial is testingResistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsWho this might be right forNon-small Cell Lung Cancer AstraZeneca 44
Not applicableStudy completedNCT03133234What this trial is testingEffect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCWho this might be right forT790M Positive NSCLC Patients AstraZeneca 47
Early research (Phase 1)Ended earlyNCT04622072What this trial is testingXZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Sihuan Pharmaceutical Holdings Group Ltd. 21
Testing effectiveness (Phase 2)UnknownNCT03300115What this trial is testingClinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCWho this might be right forMetastatic Non-small Cell Lung Cancer Hangzhou ACEA Pharmaceutical Research Co., Ltd. 222
Not applicableApproved For MarketingNCT04829422What this trial is testingEarly Access Program of Lazertinib in Republic of KoreaWho this might be right forLung Cancer Yuhan Corporation
Testing effectiveness (Phase 2)Study completedNCT02094261What this trial is testingPhase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursWho this might be right forNon Small Cell Lung Cancer AstraZeneca 210
Testing effectiveness (Phase 2)Study completedNCT03386955What this trial is testingBPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Beta Pharma Shanghai 215
Early research (Phase 1)Study completedNCT03516214What this trial is testingEGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsWho this might be right forBronchial Neoplasms University of Cologne 18
Testing effectiveness (Phase 2)Study completedNCT02841579What this trial is testingOsimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MWho this might be right forNon-Small Cell Lung Cancer MedSIR 22
Not applicableUnknownNCT05314296What this trial is testingOsimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI TherapyWho this might be right forNon Small Cell Lung CancerT790MEGFR Gene Mutation N.N. Blokhin National Medical Research Center of Oncology 70
Not applicableStudy completedNCT03219970What this trial is testingEfficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.Who this might be right forNon-small Cell Lung Cancer AstraZeneca 156
Large-scale testing (Phase 3)Study completedNCT02151981What this trial is testingAZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerWho this might be right forAnticancer Treatment AstraZeneca 421
Early research (Phase 1)Active Not RecruitingNCT03333343What this trial is testingStudy of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCWho this might be right forEGFR-mutant Non-small Cell Lung Cancer Novartis Pharmaceuticals 105
Large-scale testing (Phase 3)UnknownNCT02972333What this trial is testingOpen Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MWho this might be right forEGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more Shandong Cancer Hospital and Institute 150
Large-scale testing (Phase 3)Study completedNCT02997501What this trial is testingT790M Plasma Testing Methodology Comparison and Clinical ValidationWho this might be right forLung Cancer AstraZeneca 256
Not applicableStudy completedNCT03790397What this trial is testingOsimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positiveWho this might be right forNon Small Cell Lung Cancer Fundación GECP 169